Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer : Updated findings from NCIC CTG MA.17GOSS, Paul E; INGLE, James N; LIVINGSTON, Robert B et al.Journal of the National Cancer Institute. 2005, Vol 97, Num 17, pp 1262-1271, issn 0027-8874, 10 p.Article

1-2-(2,2,2-Trifluoroethoxy)ethyl-1H-pyrazolo[4,3-d]pyrimidines as potent phosphodiesterase 5 (PDE5) inhibitorsTOLLEFSON, Michael B; ACKER, Brad A; JACOBSEN, E. J et al.Bioorganic & medicinal chemistry letters (Print). 2010, Vol 20, Num 10, pp 3125-3128, issn 0960-894X, 4 p.Article

Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitorsOWEN, Dafydd R; WALKER, John K; MOLYNEAUX, John M et al.Bioorganic & medicinal chemistry letters (Print). 2009, Vol 19, Num 15, pp 4088-4091, issn 0960-894X, 4 p.Article

Silicon Carbide Power Modules for High-Temperature ApplicationsPALMER, Michael J; JOHNSON, R. Wayne; AUTRY, Tracy et al.IEEE transactions on components, packaging, and manufacturing technology (2011. Print). 2012, Vol 2, Num 1-2, pp 208-216, issn 2156-3950, 9 p.Article

Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National cancer institute of canada clinical trials group MA.17GOSS, Paul E; INGLE, James N; LIVINGSTON, Robert B et al.Journal of clinical oncology. 2007, Vol 25, Num 15, pp 2006-2011, issn 0732-183X, 6 p.Article

A randomized trial of letrozole in postmenopausal women after five years oftamoxifen therapy for early-stage breast cancerGOSS, Paul E; INGLE, James N; LIVINGSTON, Robert B et al.The New England journal of medicine. 2003, Vol 349, Num 19, pp 1793-1802, issn 0028-4793, 10 p.Article

1-(2-Ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidines as potent phosphodiesterase 5 (PDE5) inhibitorsTOLLEFSON, Michael B; ACKER, Brad A; JACOBSEN, E. J et al.Bioorganic & medicinal chemistry letters (Print). 2010, Vol 20, Num 10, pp 3120-3124, issn 0960-894X, 5 p.Article

The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agentsDENINNO, Michael P; ANDREWS, Melissa; YU, Li J et al.Bioorganic & medicinal chemistry letters (Print). 2009, Vol 19, Num 9, pp 2537-2541, issn 0960-894X, 5 p.Article

Efficacy, Toxicity, and Quality of Life in Older Women With Early-Stage Breast Cancer Treated With Letrozole or Placebo After 5 Years of Tamoxifen : NCIC CTG Intergroup Trial MA. 17MUSS, Hyman B; DONGSHENG TU; PRITCHARD, Kathleen I et al.Journal of clinical oncology. 2008, Vol 26, Num 12, pp 1956-1964, issn 0732-183X, 9 p.Article

Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen : A companion study to NCIC CTG MA.17PEREZ, Edith A; JOSSE, Robert G; SHIFANG LIU et al.Journal of clinical oncology. 2006, Vol 24, Num 22, pp 3629-3635, issn 0732-183X, 7 p.Article

Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trialINGLE, James N; DONGSHENG TU; LIVINGSTON, Robert B et al.Breast cancer research and treatment. 2006, Vol 99, Num 3, pp 295-300, issn 0167-6806, 6 p.Article

Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15)BEZJAK, Andrea; DIXON, Peter; SMITH, Colum et al.International journal of radiation oncology, biology, physics. 2002, Vol 54, Num 3, pp 719-728, issn 0360-3016, 10 p.Article